{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:11:50Z","timestamp":1791594710663,"version":"4.3.4"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T00:00:00Z","timestamp":1523664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate whether the clinical benefit and relapse rates in anti\u2010muscle\u2010specific kinase (Mu<jats:styled-content style=\"fixed-case\">SK<\/jats:styled-content>) myasthenia gravis (<jats:styled-content style=\"fixed-case\">MG<\/jats:styled-content>) differ depending on the protocol of rituximab followed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective multicentre study in patients with Mu<jats:styled-content style=\"fixed-case\">SK MG<\/jats:styled-content> compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan\u2013Meier methods and survival analyses were undertaken using Cox proportional\u2010hazards models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010five patients were included: 11 treated with protocol 4 + 2 (375 mg\/m<jats:sup>2<\/jats:sup>\/4 weeks, then monthly for 2 months), five treated with protocol 1 + 1 (two 1 g doses 2 weeks apart), and nine treated with protocol 4 (375 mg\/m<jats:sup>2<\/jats:sup>\/4 weeks). Mean follow\u2010up was 5.0 years (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 3.3). Relapse occurred in 18.2%, 80%, and 33.3%, and mean time to relapse was 3.5 (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 1.5), 1.1 (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 0.4), and 2.5 (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 1.4) years, respectively. Based on Kaplan\u2013Meier estimates, patients treated with protocol 4 + 2 had fewer and later relapses than patients treated with the other two protocols (log\u2010rank test <jats:italic>P<\/jats:italic> = 0.0001). Patients treated with protocol 1 + 1 had a higher risk of relapse than patients treated with protocol 4 + 2 (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 112.8, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 5.7\u20132250.4, <jats:italic>P<\/jats:italic> = 0.002). Patients treated with protocol 4 showed a trend to a higher risk of relapse than those treated with protocol 4 + 2 (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 9.2, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.9\u201391.8, <jats:italic>P<\/jats:italic> = 0.059).<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>This study provides class <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> evidence that the 4 + 2 rituximab protocol has a lower clinical relapse rate and produces a more durable response than the 1 + 1 and 4 protocols in patients with Mu<jats:styled-content style=\"fixed-case\">SK MG<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acn3.564","type":"journal-article","created":{"date-parts":[[2018,4,15]],"date-time":"2018-04-15T00:39:45Z","timestamp":1523752785000},"page":"710-716","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The impact of rituximab infusion protocol on the long\u2010term outcome in anti\u2010MuSK myasthenia gravis"],"prefix":"10.1002","volume":"5","author":[{"given":"Elena","family":"Cort\u00e9s\u2010Vicente","sequence":"first","affiliation":[{"name":"Neuromuscular Diseases Unit Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Centre for Biomedical Network Research on Rare Diseases (CIBERER) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Rojas\u2010Garcia","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Centre for Biomedical Network Research on Rare Diseases (CIBERER) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"D\u00edaz\u2010Manera","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Centre for Biomedical Network Research on Rare Diseases (CIBERER) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Querol","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Centre for Biomedical Network Research on Rare Diseases (CIBERER) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit Department of Neurology Hospital Universitari de Bellvitge \u2013 IDIBELL L'Hospitalet de Llobregat Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guerrero\u2010Sola","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit Departament of Neurology Hospital Universitario Cl\u00ednico San Carlos Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Mu\u00f1oz\u2010Blanco","sequence":"additional","affiliation":[{"name":"ALS\u2010Neuromuscular Unit Department of Neurology Hospital General Universitario Gregorio Mara\u00f1\u00f3n IISGM Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Eulalio","family":"B\u00e1rcena\u2010Llona","sequence":"additional","affiliation":[{"name":"Department of Neurology Hospital Universitario Cruces Baracaldo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celedonio","family":"M\u00e1rquez\u2010Infante","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit Departament of Neurology and Neurophysiology Hospital Universitario Virgen del Roc\u00edo Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pardo","sequence":"additional","affiliation":[{"name":"Department of Neurology Hospital Cl\u00ednico Santiago de Compostela Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mar\u00eda","family":"Mart\u00ednez\u2010Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Neurology Hospital Juan Ram\u00f3n Jim\u00e9nez Huelva Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Us\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Neurology Hospital Son Ll\u00e0tzer Palma de Mallorca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Oliva\u2010Nacarino","sequence":"additional","affiliation":[{"name":"Department of Neurology Hospital Universitario Central de Asturias Oviedo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Sevilla","sequence":"additional","affiliation":[{"name":"Centre for Biomedical Network Research on Rare Diseases (CIBERER) Madrid Spain"},{"name":"Neuromuscular Unit Department of Neurology Hospital Universitari i Polit\u00e8cnic La Fe Valencia Spain"},{"name":"Department of Medicine University of Valencia Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Illa","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit Department of Neurology Hospital de la Santa Creu i Sant Pau Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Centre for Biomedical Network Research on Rare Diseases (CIBERER) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.008"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51285.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.27.4.307"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e328364c079"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880171208"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20061"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000357"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313944110"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg223"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1042\/bst0250705"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265313133"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST0300824"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.863"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02399.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4190"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23794"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000205"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000149"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.1.91"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh469"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70137-X"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23577"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3506-13.2013"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12758"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000445841"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000202"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000077"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.311"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601415"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115723"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94263"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facn3.564","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:44:55Z","timestamp":1695505495000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,14]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/acn3.564"],"URL":"https:\/\/doi.org\/10.1002\/acn3.564","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,14]]},"assertion":[{"value":"2018-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}